The combination of bendamustine, bortezomib, and dexamethasone was reported to be effective in achieving overall response rates in myeloma.
Research is needed to identify the potentially overlapping molecular pathways involved in autoimmunity and B-cell neoplasms.
Cancer Therapy Advisor interviewed Dr Bakal about this new approach to analyzing cell shape and its potential to affect breast cancer treatment.
Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.
At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.
At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progress in the treatment of bladder cancer.
The cost of treating CML can be crippling, and it's unclear whether future approvals or policies will improve the financial toxicity associated with the disease.
While women who lost more than 5 kg after age 18 were at a 23% reduced risk for breast cancer, those who gained more than 30 kg were at a 32% increased risk.
The American Society of Clinical Oncology (ASCO) named Immunotherapy 2.0 the "advance of the year."
Patients who are treated for multiple myeloma at high-volume cancer centers have better survival outcomes than those receiving care at low-volume facilities.
Scientists are testing immune checkpoint proteins, CD8 T cell clonal expansion, mutational load, and PSA levels as predictive biomarkers for prostate cancer immunotherapy outcomes.
Smoking cessation may improve survival regardless of the type of cancer diagnosed, due to a reduction in comorbidities.
Despite the success of targeted therapy in other cancers, targeted therapy has failed to improve outcomes in triple-negative breast cancer.
Selinexor represents a much-needed therapeutic addition to the available agents for the treatment of heavily pre-treated patients with few options.
Specialized treatment centers would bring together oncology faculty capable of managing the administration of drugs, including immunotherapies.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immunotherapy and the Future of Prostate Cancer Treatment
- Explaining Androgen Receptor-indifferent Prostate Cancer
- Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Are Feasible
- Navigating the Costs of Chronic Myeloid Leukemia: A Glimpse Into the Future
- NSCLC: No Overall Survival Difference Between Afatinib and Gefitinib